Infectious Diseases Laboratory, 4th Department of Internal Medicine, National and Kapodistrian University of Athens, Athens, Greece.
1st Internal Medicine & Infectious Diseases Department, Hygeia General Hospital, Athens, Greece.
Euro Surveill. 2020 Jan;25(3). doi: 10.2807/1560-7917.ES.2020.25.3.2000028.
From September to October 2019, seven patients colonised or infected with a ceftazidime-avibactam (CZA)-resistant carbapenemase (KPC)-2-producing were detected in two intensive care units of a Greek general hospital. The outbreak strain was sequence type (ST)147 and co-produced KPC-2 and the novel plasmid-borne Vietnamese extended-spectrum β-lactamase (VEB)-25 harbouring a K234R substitution associated with CZA resistance. Epidemiological investigations revealed that the resistance was probably acquired by horizontal transmission independently from previous CZA exposure.
2019 年 9 月至 10 月,在希腊一家综合医院的两个重症监护病房中,检测到 7 例定植或感染产头孢他啶-阿维巴坦(CZA)耐药碳青霉烯酶(KPC)-2 的患者。暴发菌株为序列型(ST)147,同时产生 KPC-2 和新型质粒介导的越南超广谱β-内酰胺酶(VEB)-25,该酶携带与 CZA 耐药相关的 K234R 取代。流行病学调查显示,耐药性可能是通过水平传播获得的,与之前的 CZA 暴露无关。